title: Prognostic value of the copper transporters, CTR1 and CTR2, in patients with ovarian carcinoma receiving platinum-based chemotherapy.
abstract: OBJECTIVE
  CTR1 and CTR2 are copper transporters that have been associated with platinum sensitivity in several human cancers. We investigated the prognostic significance of CTR1 and CTR2 in women with ovarian carcinoma.
  
  
  METHODS
  We evaluated the expression of CTR1 and CTR2 using real-time PCR in 40 women with ovarian carcinoma (IIb=2, IIIb=2, IIIc=30, IV=6). We compared the expression of CTR1 and CTR2 with participants' clinicopathological findings.
  
  
  RESULTS
  We found lower expression of CTR1 and CTR2 mRNA in ovarian cancer cells against normal ovarian tissue with statistically significant differences (p=0.018 and 0.011, respectively). High CTR1 expression was a prognostic factor for improved survival after adjusting for age, tumor grade, stage, residual tumor, and CTR2 mRNA expression (HR, 0.35; 95% CI, 0.15-0.84). However, CTR2 expression did not exhibit any prognostic significance. Of the 20 women with elevated CTR1 expression, 17 (85%) were sensitive to platinum-based chemotherapy. Of the 7 women with low CTR1 expression and high CTR2 expression, 6 (85.7%) were resistant to platinum-based chemotherapy and had the shortest progression-free survival of all women in our study sample.
  
  
  CONCLUSIONS
  In our sample of 40 women with ovarian carcinoma, high CTR1 expression was significantly associated with sensitivity to platinum-based chemotherapy and longer progression-free survival. Conversely, low CTR1 expression and high CTR2 expression were significantly associated with resistance to platinum-based chemotherapy and the shortest survival.
authors.affiliation: Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710, Republic of Korea.
authors.forename: Yoo-Young
authors.initials: YY
authors.lastname: Lee
authors.forename: Chel Hun
authors.initials: CH
authors.lastname: Choi
authors.forename: In-Gu
authors.initials: IG
authors.lastname: Do
authors.forename: Sang Yong
authors.initials: SY
authors.lastname: Song
authors.forename: Wooseok
authors.initials: W
authors.lastname: Lee
authors.forename: Hwang Shin
authors.initials: HS
authors.lastname: Park
authors.forename: Tae Jong
authors.initials: TJ
authors.lastname: Song
authors.forename: Min Kyu
authors.initials: MK
authors.lastname: Kim
authors.forename: Tae-Joong
authors.initials: TJ
authors.lastname: Kim
authors.forename: Jeong-Won
authors.initials: JW
authors.lastname: Lee
authors.forename: Duk-Soo
authors.initials: DS
authors.lastname: Bae
authors.forename: Byoung-Gie
authors.initials: BG
authors.lastname: Kim
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000627:therapeutic use*; D027682:Cation Transport Proteins / Q000032:analysis / Q000235:genetics / Q000502:physiology*; D000079923:Copper Transporter 1; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D016133:Polymerase Chain Reaction; D011379:Prognosis; D012333:RNA, Messenger / Q000032:analysis; D012189:Retrospective Studies; D000080083:SLC31 Proteins
chemical_list: D027682:Cation Transport Proteins; D000079923:Copper Transporter 1; D012333:RNA, Messenger; D000080083:SLC31 Proteins; C490079:SLC31A1 protein, human; C524078:SLC31A2 protein, human; D016190:Carboplatin